Research Square

Preprints are preliminary reports that have not undergone peer review.
They should not be considered conclusive, used to inform clinical practice,
or referenced by the media as validated information.

# Clinical impact of Letermovir primary prophylaxis on cytomegalovirus-related complications and 1 survival in hematopoietic cell transplant recipients: Data from a prospective multicenter study in Latin

**Fabián Herrera**

fabian1961@gmail.com

Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno

**Diego Torres**

Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno

**Lucas Tula**

Hospital de Alta Complejidad El Cruce, Provincia de Buenos Aires

**Noelia Mañez**

Hospital Italiano de Buenos Aires

**Florencia Otermin**

Hospital Italiano de La Plata, Provincia de Buenos Aires

**Ana Laborde**

Fundación de lucha contra la leucemia (FUNDALEU)

**María Laura Pereyra**

Hospital Universitario Austral, Provincia de Buenos Aires

**Manuel Alderete**

Instituto Alexander Fleming

**Hugo Peretti**

Sanatorio Británico de Rosario

**Roy F. Chemaly**

The University of Texas MD Anderson Cancer Center

**María José Eusebio**

Hospital Británico de Buenos Aires

**Silvina García Rojas**

Hospital Británico de Buenos Aires

**Nicolás Lasserre**

Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno

**Julieta Dalmarori**

Hospital de Alta Complejidad El Cruce, Provincia de Buenos Aires

**Facundo Argüello**
Hospital Italiano de Buenos Aires
**María Elena Silva**
Hospital Italiano de La Plata, Provincia de Buenos Aires
**María Luz González Ibáñez**
Fundación de lucha contra la leucemia (FUNDALEU)
**Rocío Gago**
Hospital Universitario Austral, Provincia de Buenos Aires
**Santiago Adriani**
Sanatorio Británico de Rosario
**Jorge López Camelo**
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno
**Rosana Jordán**
Hospital Británico de Buenos Aires

---

**Research Article**

**Keywords:**

**Posted Date:** November 9th, 2026

**DOI:** https://doi.org/10.21203/rs.3.rs-10100455/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License

**Additional Declarations:** Competing interest reported. F.H. has received speaker honoraria and/or grants from Merck, Sharp & Dohme (MSD), Takeda, Pfizer, Gilead, TEVA, Biomerieux, and Knight Therapeutics. D.T. has received speaker honoraria and/or grants from Gilead, Knight Therapeutics, MSD, Pfizer, and GlaxoSmithKline. L.T. received speaker honoraria from MSD, Takeda and Knight Therapeutics. M.L.P received speaker honoraria from Takeda. J.D. received speaker honoraria from MSD. R.F.C. serves as a consultant, speaker, or scientific adviser for ADMA Biologics, Janssen, Merck/MSD, Partner Therapeutics, Takeda, Shionogi, AiCuris, Roche/Genentech, Astellas, Adagio Therapeutics, Tether, Oxford Immunotec, Karius, and Ansun Pharmaceuticals. He received research grants paid to his institution from Merck/MSD, Karius, AiCuris, Ansun Pharmaceuticals, Takeda, Roche/Genentech, Oxford Immunotec, Freestyle, and Eurons Viracor. R.J. received speaker honoraria from MSD, Pfizer, and Knight Therapeutics.

---

# Clinical impact of Letermovir primary prophylaxis on cytomegalovirus-related complications and survival in hematopoietic cell transplant recipients: Data from a prospective multicenter study in Latin America

Fabián Herrera[1], Diego Torres[1], Lucas Tula[2], Noelia Mañez[3], Florencia Otermin[4], Ana Laborde[5], María Laura Pereyra[6], Manuel Alderete[7], Hugo Peretti[8], Roy F. Chemaly[9], María José Eusebio[10], Silvina García Rojas[10], Nicolás Lasserre[1], Julieta Dalmarori[2], Facundo Argüello[3], María Elena Silva[4], María Luz González Ibáñez[5], Rocío Gago[6], Santiago Adriani[8], Jorge López Camelo[11], Rosana Jordán[10], on behalf of the REVIVIR study.

**Corresponding author**: Fabián Herrera, MD.

Fabián Herrera. Infectious Diseases Section, Department of Internal Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC). Galván 4102, Ciudad Autónoma de Buenos Aires, C1431, Argentina. Tel: 5299-0100.

E-mail address: fabian1961@gmail.com

ORCID: 0000-0001-8900-4400

Diego Torres. Infectious Diseases Section, Department of Internal Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Ciudad Autónoma de Buenos Aires, Argentina.

Lucas Tula. Infectious Diseases Service, Hospital de Alta Complejidad El Cruce, Provincia de Buenos Aires, Argentina.

Noelia Mañez. Infectious Diseases Section, Department of Internal Medicine, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.

Florencia Otermin. Infectious Diseases Service, Hospital Italiano de La Plata, Provincia de Buenos Aires, Argentina.

Ana Laborde. Infectious Diseases Service, Fundación de Lucha contra la Leucemia (FUNDALEU), Ciudad Autónoma de Buenos Aires, Argentina.

María Laura Pereyra. Infectious Diseases Service, Hospital Universitario Austral, Provincia de Buenos Aires, Argentina.

Manuel Alderete. Infectious Diseases Service, Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina.

Hugo Peretti. Hematopoietic Cell Transplant Unit, Centro de Hematología y Trasplante (CENyT), Sanatorio Británico de Rosario, Argentina.

Roy F. Chemaly. Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

María José Eusebio. Infectious Diseases Service, Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

Silvina Garcia Rojas. Infectious Diseases Service, Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.

Nicolás Lasserre. Infectious Diseases Section, Department of Internal Medicine, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Ciudad Autónoma de Buenos Aires, Argentina.

Julieta Dalmaroni. Hematology Service, Hospital de Alta Complejidad El Cruce, Provincia de Buenos Aires, Argentina.

Facundo Arguello. Infectious Diseases Section, Department of Internal Medicine, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.

María Elena Silva. Infectious Diseases Service, Hospital Italiano de La Plata, Provincia de Buenos Aires, Argentina.

María Luz González Ibáñez. Infectious Diseases Service, Fundación de Lucha contra la Leucemia (FUNDALEU), Ciudad Autónoma de Buenos Aires, Argentina.

Rocío Gago. Infectious Diseases Service, Hospital Universitario Austral, Ciudad Autónoma de Buenos Aires, Argentina

Santiago Adriani. Haematopoietic Cell Transplant Unit, Centro de Hematología y Trasplante (CENyT), Sanatorio Británico de Rosario, Argentina

Jorge López Camelo. CEMIC-CONICET Research Unit, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Ciudad Autónoma de Buenos Aires, Argentina.

Rosana Jordán. Infectious Diseases Unit, Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina

REVIVIR study (Registry of Cytomegalovirus Prevention with Letermovir in HCT Patients).

**Keywords**: letermovir, prophylaxis, cytomegalovirus, hematopoietic cell transplant, survival.

**Purpose:** To compare the incidence of clinically significant cytomegalovirus infection (CS-CMVi), CMV disease (CMV-d) and CMV-related rehospitalization in patients with allogeneic hematopoietic cell transplant (alloHCT) who received letermovir (LET) primary prophylaxis or were managed with preemptive therapy (PET). We further aimed to identify risk factors for overall mortality at day 200 post-HCT.

**Methods**: A prospective, observational, multicenter cohort study was conducted at 9 centers in Argentina from October 2020 to September 2025. Adult CMV-seropositive alloHCT recipients were included and followed through day 200 post-HCT. A propensity score (PS) was used to balance baseline covariates. An adjusted conditional multivariate logistic regression analysis including PS was implemented to identify independent risk factors for 200-day overall mortality.

**Results**: Five hundred and fifty-one patients were included (PET: 346 and LET: 205). CMV seronegative donors, alternative donors, and post-transplant cyclophosphamide administration were compared in PET vs. LET groups: 12.4% vs. 30.7% ($p<0.0001$), 56.9% vs. 87.3% ($p<0.0001$), and 51.7% vs. 80.5% ($p<0.0001$), respectively. High-risk stratification for the development of CMV-d was 88.2% in the PET group compared with 97.1% in the LET group ($p=0.0003$). CS-CMVi, CMV-d, and CMV-related rehospitalization at day 100 post-HCT in the PET vs. LET groups were: 54.3% vs. 7.3% ($p<0.0001$), 7.5% vs. 0% ($p=0.0001$), and 37.9% vs. 10.2% ($p<0.0001$), respectively. Multivariate analysis adjusted for PS identified the following risk factors for mortality: primary graft failure, OR 16.57, 95% CI, 5.23-52.52 ($p<0.0001$), GvHD with high dose of corticosteroids, OR 1.9, 95% CI, 1.19-3.04 ($p=0.007$), and lymphopenia < 300/ $mm^3$, OR 1.78, 95% CI, 1.10-2.89 ($p=0.019$). LET primary prophylaxis was a protective factor for survival, OR 0.51, 95% CI, 0.29-0.89 ($p=0.018$).

**Conclusions**: LET primary prophylaxis effectively prevented CMV-related complications, reduced rehospitalizations, and had a benefit on overall survival in seropositive alloHCT recipients.

## Introduction

Cytomegalovirus infection (CMVi) remains the most common clinically significant infection after allogeneic hematopoietic cell transplantation (alloHCT), with high morbidity and mortality rates. A randomized controlled trial demonstrated that Letermovir (LET) primary prophylaxis in CMV-seropositive alloHCT recipients through day 100 after transplantation proved effective in reducing CMVi reactivation (r-CMVi), clinically significant infection (CS-CMVi), and end organ disease (CMV-d). Compared with preemptive therapy (PET), patients had lower overall mortality at week 24 [1]. Subsequently, two post hoc analyses of this study showed that patients who received LET had lower overall mortality at week 48 and lower rates of CMV-associated and all-cause rehospitalizations [2,3]. LET extended administration to patients who continue at high risk for CMVi complications through day 200 post-HCT proved to significantly reduce CS-CMVi [4].

Many real-life studies confirm these findings and have shown overall survival benefits in terms of one-year non-relapse mortality, especially in patients at high risk for CMV-d, such as those with T-cell depletion [5-7]. Therefore, LET is currently recommended by ECIL and ASTC guidelines [8,9]. Notwithstanding that, and as a result of its high cost, it is not available in many low- and middle-income countries like those in Latin America.

Several large retrospective studies have shown the clinical benefits of LET. However, to the best of our knowledge, no prospective multicenter studies have been published on risk factors for mortality and the benefit of LET in overall survival.

The main purposes of this research were to compare the incidence of CMV-related complications, such CS-CMVi and CMV-d, as well as the reduction in CMV-related rehospitalization at days 100 and 200 post-HCT between patients receiving LET and those managed with PET. Secondary objectives included identification of risk factors for overall mortality (defined as death for any reason) at day 200 post-HCT, and assessment of the impact of LET on survival.

.

## Material and methods

### Setting, patients, and study design

A prospective, observational, multicenter cohort study was conducted at 9 centers in Argentina from 1 October 2020 to 30 September 2025. All adult patients (≥ 18 years of age) who had undergone a first alloHCT and received primary prophylaxis with LET or were managed with PET were evaluated.

Patients were excluded provided that they were CMV seronegative, or had died before day 10 post-HCT with no r-CMVi or were lost to follow-up.

Demographic, clinical, diagnostic, and outcome variables were evaluated and appropriately defined to avoid inconsistencies, and missing data were not allowed. Follow-up was conducted through day 200 post-HCT or longer in patients who remained at risk for CS-CMVi or CMV-d, by direct patient care in accordance with standardized protocols at each center. Data were obtained from databases of the Infectious Diseases Units, the Hematology Laboratory, and the Virology Laboratory.

Patient data were recorded with RedCap (Research Electronic Data Capture) software, and the study was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations [10].

### Definitions, diagnosis and prevention modality

CMVi was defined as virus nucleic acid detection in blood, plasma, or another fluid or tissue specimen. CS-CMVi was defined as CMV-d or CMV viremia leading to PET[1]. End-organ disease definition was consistent with that applied by the Working Group of the Cytomegalovirus Drug Development Forum [1,11].

Patients were stratified according to the risk of developing CMV-d. Those presenting one or more of the following factors were classified as high risk: ex vivo T-cell depletion, in vivo T-cell depletion with antithymocyte globulin or alemtuzumab use, prednisone (or equivalent) at a dose of 1 mg or more per kilogram of body weight per day for acute graft-versus-host disease (GvHD) grade II-IV, mismatched related or unrelated

donor, haploidentical donor and cord blood transplant [1]. Allogeneic HCT presenting none of the above factors was considered low risk.

For r-CMVi diagnosis, CMV VL (viral load) was measured in plasma with real-time polymerase chain reaction (RT-PCR). Weekly monitoring started on days -2 to 10 and continued through day 200 post-HCT or beyond in patients considered at risk of late CMV-d. The lower limit of quantification was determined according to the method used at each center.

LET administered orally was started after an undetectable CMV VL within the previous 48 hours. It was indicated from day 0 to 10 after HCT and continued through at least day 100 post-HCT. LET was prescribed according to the availability of the drug at each center. Patients received LET at a standard dose of 480 mg/day, while those on cyclosporine received 240 mg/day.

Patients with a positive RT-PCR result who met the institutional threshold for PET, or had a diagnosis of CMV-d, were initiated on appropriate antiviral therapy with ganciclovir, valganciclovir, or foscarnet according to institutional guidelines at each center, given the lack of consensus on this issue.

LET primary prophylaxis and PET were considered mutually exclusive initial prevention strategies. However, patients receiving LET could subsequently receive antiviral therapy in case of CS-CMVi or CMV-d development after prophylaxis initiation. Therefore, LET was analyzed as the primary prevention strategy, whereas post-baseline antiviral treatment was deemed part of the clinical course.

All patients were administered prophylaxis with acyclovir or valacyclovir and sulphamethoxazole-trimethoprim through at least 1 year post-HCT. They received antifungal prophylaxis through at least day 75 post-HCT according to IDSA and GITMO guidelines [12,13]. Definitions and grading of acute GvHD were consistent with the MAGIC consortium [14].

**Sample size**

The study sample size was based on both the available prospective cohort and the minimum detectable differences for the main CMV-related outcomes. Assuming a two-sided alpha level of 0.05, 80% statistical power, approximately 200 patients in the LET group and 350 patients in the PET group, the study had sufficient power to detect a 12 percentage point absolute difference in CS-CMVi, with an expected incidence

of 50% in the PET group. For CMV-d, assuming an expected incidence of 8% in the PET group, an 8 percentage point minimum detectable absolute difference was observed.

This was an observational study with non-randomized treatment allocation. Therefore, the sample size calculation was considered descriptive and supportive rather than a formal calculation for randomized trials.

**Statistical analysis**

Continuous variables were summarized as median and interquartile range or mean and standard deviation, according to their distribution. Categorical variables were summarized as absolute frequencies and percentages. Baseline characteristics were compared between the LET and PET groups using the Mann-Whitney U test for continuous variables and the chi-square test or Fisher exact test for categorical variables, as appropriate.

The primary outcomes included clinically CS-CMVi and CMV-d. The secondary outcome was overall mortality at day 200 post-HCT. They were analyzed according to the treatment strategy defined at baseline or at treatment initiation. LET timing and PET initiation were considered to avoid immortal time bias. CS-CMVi and CMV-d cumulative incidence was estimated with the Kaplan-Meier method.

A multivariate logistic regression model was used to identify risk factors for overall mortality at day 200 post-HCT. Variables with $p < 0.05$ in the univariate analysis were included in the multivariate model.

Since LET primary prophylaxis was not randomly assigned, a propensity score (PS) approach was used to reduce confounding by indication. PS was estimated using multivariate logistic regression, with LET primary prophylaxis as the dependent variable. Only baseline or pre-treatment clinical and transplant-related variables were included in the PS model. Covariates were selected a priori based on clinical relevance and their potential associations with both treatment allocation and mortality. They included patient age, refractory malignancy, matched related donor, haploidentical related donor, T-cell depletion, post-transplant cyclophosphamide (PTCy) administration, CMV seronegative donor and high-risk of CMV-d stratification. Variables reported after treatment initiation were not included in the main adjustment set.

Patients were stratified into PS quintiles. Covariate balance between the LET and PET groups was assessed before and after PS stratification using standardized mean differences with values below 0.10 considered acceptable.

The association between LET primary prophylaxis and overall mortality at day 200 post-HCT was estimated using logistic regression adjusted for PS strata. For CMV-related outcomes, cumulative incidence was interpreted considering death before CMVi or CMV-d as a competing event.

All analyses were performed using Stata software, version 18.0 (StataCorp LLC, College Station, TX, USA). A two-tailed p-value $<0.05$ was considered statistically significant.

**Results**

A total of 650 patients were evaluated and 99 were excluded because they failed to meet the eligibility criteria (Figure 1). The total study population consisted of 551 patients: 346 (62.8%) were managed with PET and 205 (37.2%) received LET. Baseline characteristics are described in Table 1. There was a male predominance, with a median age of 43 years, which was higher in the LET group. The most frequent underlying diseases were acute myeloblastic leukemia and acute lymphoblastic leukemia, with a large proportion being in complete remission in both groups, while refractory disease was more common in the LET group. In terms of type of transplant, differences were observed between the cohorts: matched related donors were more frequent in the PET group, whereas most patients in the LET group received an HCT from an alternative donor. Other significant differences included higher PTCy use and CMV-seronegative donors, as well as lower lymphocyte counts at 100 days post-HCT in the LET group. In addition, the median time to granulocyte engraftment was longer in this group.

The characteristics of acute and chronic GvHD are shown in Table 2. There were no differences between the groups in the incidence or severity of acute GvHD, whereas chronic GvHD was less frequent in the LET group. All patients had risk factors for CS-CMVi and CMV-d, as outlined in Table 3. Median risk factors were higher in the LET group, and most patients were stratified as high risk for developing CMV-d.

The outcomes are depicted in Table 4 and Figure 2. Patients in the LET cohort had a significantly lower rate of CS-CMVi, CMV-d and CMV-related rehospitalization than those in the PET cohort. In the latter group more

than one CS-CMVi episode was frequently observed. On the other hand, a larger number of patients in the LET cohort developed CS-CMVi between days 100 and 200 post-HCT (27, 13.2% vs. 4, 1.2%, p<0.0001). Overall mortality at day 200 post-HCT was similar between the groups; in addition, CMV-related mortality was very low, with no deaths reported in the LET group. In the univariate analysis factors associated with mortality are depicted in Table 5.

The results of the multivariate analysis adjusted for PS are shown in Table 6. The independent risk factors for 200-day overall mortality were primary graft failure, high-dose corticosteroid use for acute GvHD, and lymphopenia, whereas LET primary prophylaxis was a protective factor for survival.

## Discussion

This study showed that LET primary prophylaxis reduced the incidence of CS-CMVi, CMVd, and CMV-related rehospitalization. It also identified the risk factors for 200-day overall mortality and the role of LET on survival. The major findings of the present study include significant differences in baseline characteristics between the cohorts. Patients in the LET group were older, had a higher rate of refractory disease, had more haploidentical transplants and PTCy use. This finding was consistent with the fact that the health-care insurance system in Argentina does not usually provide LET unless high-risk patients are involved. The randomized study by Marty et al. reported otherwise, with cohorts being readily comparable and only one third being at high risk for developing CMV-d [1]. Thus, the comparison in our study could be biased, though partially, given the study prospective design, where all variables were defined, missing data were not allowed and PS was performed.

Unlike Marty's and many other real-life studies, median time to granulocyte engraftment was longer in the LET group. A delay in hematopoietic recovery has been reported in haploidentical HCT and in those who received PTCy [15,16]. This could explain what was observed in the LET cohort.

A lower proportion of patients in the LET cohort developed chronic GvHD. The same was reported in a study that included Alemtuzumab T-cell-depleted alloHCT recipients; whereas another research revealed opposite findings [17,18]. Chronic GvHD causes long-term morbidity and mortality, as well as a negative impact on health-related quality of life [19,20]. Therefore, GvHD-free/relapse-free survival is crucial in alloHCT patients.

More patients in the LET group received PTCy, which could explain the lower rate of chronic GvHD. This is still a controversial issue, since some studies reported the same rate of chronic GvHD in patients who received PTCy as in those who did not [21,22]. Should LET play a role, this significant finding might be addressed in larger studies.

Most patients in the LET cohort had a high burden of risk factors for CS-CMVi and CMV-d and were mostly at high risk of developing CMV-d. However, the incidence of these complications was low through day 100 post-HCT and no patients developed CMV-d. A meta-analysis of 48 real-life studies in alloHCT adults showed that LET effectively reduced the risk of CMV-related complications and overall and non-related mortality beyond day 200 post-HCT [23]. In addition, LET proved to reduce refractory CMVi [24].

Patients in the LET cohort had a low rate of CMV-related rehospitalization. This is crucial, as hospitalization can lead to clinical complications with a negative impact on patients' quality of life. In addition, most patients receive either ganciclovir or foscarnet, which often have adverse effects. Thus, CS-CMVi and CMV-d significantly increase healthcare costs. In this regard, several studies have shown that LET is a cost-effective strategy [25-27].

Thirteen percent of the patients developed CS-CMVi after LET discontinuation between days 100 and 200 post-HCT. They had lower lymphocyte counts by day 100 post-HCT, had received more transplants from haploidentical donors and more PTCy compared to those in the PET cohort, which could explain this fact [28]. On the other hand, LET impairs T cells and “memory-like” NK-cell reconstitution, which could increase late CS-CMVi and CMV-d [29,30]. Both the randomized clinical trials and some real-life studies showed a high rate of CMV-related complications after discontinuation of LET [1,4,31]. Therefore, identifying patients at high risk for CMV-related complications by day 100 after alloHCT is crucial for considering an extension of LET prophylaxis. In this sense, the REACT study demonstrated that measurement of CMV cell-mediated immunity by ELISPOT can identify patients with low immunity and at risk of developing CS-CMVi [32]. Recently, ELISPOT has also been shown to be a good predictor of CS-CMVi in alloHCT patients receiving LET [33]. Unfortunately, this test is neither available in Argentina nor in most Latin American countries.

The risk factors for 200-day overall mortality were accurately identified by multivariate analysis adjusted for PS, and LET was a protective factor for overall survival. These findings indicate that all CMV-seropositive alloHCT recipients should receive LET for at least 100 days after HCT. In addition, high-risk patients, such as those with high doses of corticosteroids for acute GvHD and lymphopenia, should continue LET for longer periods, at least until these conditions are managed.

Our study has some limitations that should be considered. First, one-year non-relapse and overall mortality were not the study objective, and therefore were not analyzed. On the other hand, our study showed survival benefits at 200 days post-HCT, which should also be considered when prescribing LET. Second, CMV VL threshold for initiating PET was not uniform, as it was chosen according to standardized protocols at each center; however, there is no consensus on CMV VL threshold in the literature. Third, we failed to collect the adverse effects information of the antiviral medications used for PET. This could have been useful to measure the negative impact of this strategy.

The strengths of our study rely on its prospective and multicenter design. Moreover, the real-life data provided for this design may reveal the country scenario and help other countries in Latin America.

In summary, LET primary prophylaxis effectively prevented CMV-related complications, reduced rehospitalizations, and had a benefit on overall survival in seropositive alloHCT recipients. Therefore, strategies should be implemented to facilitate access to this antiviral drug in Latin American countries.

**Members of the REVIVIR study**: Fabián Herrera, Diego Torres, Noelia Mañez, Hugo Peretti, Manuel Alderete, Ana Laborde, Lucas Tula, María L. Pereyra, Florencia Otermin, Silvina García Rojas, María J. Eusebio, Facundo Arguello, Santiago Adriani, María L. Gonzáles Ibáñez, Julieta Dalmaroni, Rocío Gago, María E. Silva, Claudia Salgueira, Rosana Jordán, Cristina Videla, Lucas H. Olivieri, Martín Cañete, Alan H. Gómez, Vanesa Romano, Marina S. Medina and Martín Rolan.

**Acknowledgements:** We thank Valeria Melia, scientific translator at CEMIC Research Unit, for the English edition of the manuscript. We thank all the hematologists who provided databases from Hematology Units: Leandro Riera, Patricio Duarte, Juliana Martínez Rolón, Guillermina Remaggi, Olivia Gelo, Cecilia Foncuberta,

Jorge Alberbide, Silvina Palmer and Micaela Quarchioni. We thank Fernando Poletta, CONICET Unit Director, for his advice on the statistical analysis.

**Authors' Contribution**

Conceptualization: F.H., D.T., R.J. Methodology: F.H., D.T., R.J., J.L.C. Software: D.T. and J.L.C. Formal analysis: D.T. and J.L.C. Investigation: L.T., N.M., F.O., A.L., M.L.P., M.A., H.P., M.J.E., S.G.R., N.L., J.D., F.A., M.E.S., M.L.G.I., R.G., S.A. Writing: original draft preparation: F.H. Writing: review and editing: D.T., R.J. and R.F.C. All authors have read and agreed to the manuscript.

**Funding**

This study has not been funded.

**Data Availability Statement:** Data is available from the corresponding author upon request.

**Declarations**

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki and was approved by CEMIC Ethics Committee on 1st October 2020 (Approval number 1474) and by the ethics committees from the different participating institutions. Patient consent was waived by the Ethics Committee according to Data Protection Law 25326, section 7, subsection 2.

**Competing of interests**

F.H. has received speaker honoraria and/or grants from Merck, Sharp & Dohme (MSD), Takeda, Pfizer, Gilead, TEVA, Biomerieux, and Knight Therapeutics. D.T. has received speaker honoraria and/or grants from Gilead, Knight Therapeutics, MSD, Pfizer, and GlaxoSmithKline. L.T. received speaker honoraria from MSD, Takeda and Knight Therapeutics. M.L.P received speaker honoraria from Takeda. J.D. received speaker honoraria from MSD. R.F.C. serves as a consultant, speaker, or scientific adviser for ADMA Biologics, Janssen, Merck/MSD, Partner Therapeutics, Takeda, Shionogi, AiCuris, Roche/Genentech, Astellas, Adagio Therapeutics, Tether, Oxford Immunotec, Karius, and Ansun Pharmaceuticals. He received research grants paid to his institution from Merck/MSD, Karius, AiCuris, Ansun Pharmaceuticals, Takeda,

Roche/Genentech, Oxford Immunotec, Freestyle, and Eurons Viracor. R.J. received speaker honoraria from MSD, Pfizer, and Knight Therapeutics.

**References**


1. Marty FM, Ljungman P, Chemaly RF, et al. (2017) Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 377 (25): 2433-2444. doi: 10.1056/NEJMoa1706640.

2. Ljungman P, Schmitt M, Marty FM, et al. (2020) A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation. Clin Infect Dis. 70 (8): 1525-1533. doi: 10.1093/cid/ciz490.

3. Golan Y, Tang Y, Mt-Isa S, Wan H, Teal V, Badshah C, Dadwal S. (2021) Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial. Pharmacoecon Open. 5 (3): 469-473. doi: 10.1007/s41669-021-00264-9.

4. Russo D, Schmitt M, Pilorge S, Stelljes M, Kawakita T, Teal VL, Haber B, Bopp C, Dadwal SS, Badshah C. (2024) Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 11 (2): e127-e135. doi: 10.1016/S2352-3026(23)00344-7.

5. Su Y, Stern A, Karantoni E, Nawar T, Han G, Zavras P, Dumke H, Cho C, Tamari R, Shaffer B, Giralt S, Jakubowski A, Perales MA, Papanicolaou G. (2022) Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study. Clin Infect Dis. 75 (5): 795-804. doi: 10.1093/cid/ciab1064.

6. Johnsrud JJ, Nguyen IT, Domingo W, Narasimhan B, Efron B, Brown JW. (2020) Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following

Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 26 (10): 1963-1970. doi: 10.1016/j.bbmt.2020.07.002.

7. Febres-Aldana A, Khawaja F, Morado-Aramburo O, et al. (2024) Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience. Clin Microbiol Infect. 30 (6): 803-809. doi: 10.1016/j.cmi.2024.03.001.

8. Khawaja F, Zamora D, Yong MK, Hakki M, Goscicki BK, Danziger-Isakov L, Lin A, Carpenter PA, Boeckh M, Papanicolaou GA, Dadwal SS, Chemaly RF. (2025) American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients. Transplant Cell Ther. 31(10): 727-741. doi: 10.1016/j.jtct.2025.06.025.

9. Ljungman P, Alain S, Chemaly RF, Einsele H, Galaverna F, Hirsch HH, Sadowska-Klasa A, Navarro D, Styczynski J, de la Camara R. (2025) Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis. 25 (8): e451-e462. doi: 10.1016/S1473-3099(25)00069-6.

10. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61 (4): 344-9. doi: 10.1016/j.jclinepi.2007.11.008.

11. Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD. (2017) Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis. 64 (1): 87-91. doi: 10.1093/cid/ciw668.

12. Girmenia C, Barosi G, Piciocchi A, et al. (2014) Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 20 (8):1080-8. doi: 10.1016/j.bbmt.2014.02.018.

391 13. Patterson TF, Thompson GR 3rd, Denning DW, et al. (2016) Practice guidelines for the diagnosis and
392 management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 63:
393 433-42. doi: 10.1093/cid/ciw326.

394 14. Harris AC, Young R, Devine S, et al. (2016) International, Multicenter Standardization of Acute Graft-
395 versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International
396 Consortium. Biol Blood Marrow Transplant. 22(1): 4-10. doi: 10.1016/j.bbmt.2015.09.001.

397 15. Desai N, Altareb M, Remberger M, et al. (2025) PTCy-based graft-versus-host disease prophylaxis for
398 matched sibling donor allogeneic hematopoietic cell transplantation. Blood Adv. 9 (3): 660-669. doi:
399 10.1182/bloodadvances.2024014781.

400 16. DeZern AE, Zahurak ML, Symons HJ, et al. (2020) Haploidentical BMT for severe aplastic anemia with
401 intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020; 4 (8):1770-1779.
402 doi: 10.1182/bloodadvances.2020001729.

403 17. Muhsen IN, Shaver KE, Wang T, Wu M, Lulla P, Ramos CA, Kamble RT, Kamble RT, Heslop HE, Carrum
404 G, Hill LC. (2024) Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell
405 Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 30 (12): 1193.e1-1193.e8. doi:
406 10.1016/j.jtct.2024.09.009.

407 18. Terao T, Matsuoka KI, Narita K, Tsushima T, Yuyama S, Kuzume A, Tabata R, Miura D, Takeuchi M,
408 Matsue K. (2021) Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of
409 Chronic Graft-*Versus*-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With
410 Post-Transplant Cyclophosphamide. Front Oncol. 11: 666774. doi: 10.3389/fonc.2021.666774.

411 19. Boyiadzis M, Arora M, Klein JP, et al. (2015) Impact of Chronic Graft-versus-Host Disease on Late Relapse
412 and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for
413 Leukemia. Clin Cancer Res. 21 (9): 2020-8. doi: 10.1158/1078-0432.CCR-14-0586.

414 20. Kurosawa S, Yamaguchi T, Oshima K, et al. (2019) Resolved versus Active Chronic Graft-versus-Host

Disease: Impact on Post-Transplantation Quality of Life. Biol Blood Marrow Transplant. 25 (9): 1851-1858. doi: 10.1016/j.bbmt.2019.05.016.

21. Jin X, Yang Y, Chen X. (2025) Post-transplant cyclophosphamide versus anti-thymocyte globulin in haploidentical stem cell transplantation: a systematic review and meta-analysis. Ann Hematol. 104 (3): 1317-1328. doi: 10.1007/s00277-025-06199-z.

22. Hong KT, Park HJ, Kim BK, An HY, Choi JY, Kang HJ. (2022) Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia. Transplant Cell Ther. 28 (4): 195.e1-195.e7. doi: 10.1016/j.jtct.2022.01.002.

23. Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF. (2022) Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies. Open Forum Infect Dis. 10 (1): ofac687. doi: 10.1093/ofid/ofac687.

24. Sassine J, Khawaja F, Shigle TL, Handy V, Foolad F, Aitken SL, Jiang Y, Champlin R, Shpall E, Rezvani K, Ariza-Heredia EJ, Chemaly RF. (2021) Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clin Infect Dis. 73 (8): 1346-1354. doi: 10.1093/cid/ciab298.

25. Alsumali A, Chemaly RF, Graham J, Jiang Y, Merchant S, Miles L, Schelfhout J, Yang J, Tang Y. (2021) Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective. J Med Virol. 93 (6): 3786-3794. doi: 10.1002/jmv.26462.

26. Restelli U, Croce D, Pacelli V, Ciceri F, Girmenia C. (2019) Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy. Infect Drug Resist. 12: 1127-1138. doi: 10.2147/IDR.S196282.

27. Qiu Y, Zhang Y, Teng M, Cheng S, Du Q, Yang L, Wang Q, Wang T, Wang Y, Dong Y, Dong H. (2024) Efficacy, Safety, and Cost-effectiveness Analysis of Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Transplantation. 108 (4): 1021-1032. doi: 10.1097/TP.0000000000004856.

28. Sadowska-Klasa A, Özkök S, Xie H, Leisenring W, Zamora D, Seo S, Lee SJ, Jerome KR, Green ML, Boeckh M. (2024) Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques. Blood Adv. 8 (14):3639-3651. doi: 10.1182/bloodadvances.2023012175.

29. Zamora D, Duke ER, Xie H, et al. (2021) Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 138 (1): 34-43. doi: 10.1182/blood.2020009396.

30. Lauruschkat CD, Muchsin I, Rein AF, et al. (2024) Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation. Blood Adv. 8 (11): 2967-2979. doi: 10.1182/bloodadvances.2023012008.

31. Lin A, Brown S, Chinapen S, Lee YJ, Seo SK, Ponce DM, Shahid Z, Giralt S, Papanicolaou GA, Perales MA, Shaffer BC. (2023) Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant. Blood Adv. 7 (23): 7153-7160. doi: 10.1182/bloodadvances.2023010966. Erratum in: Blood Adv. 2024; 8 (24): 6232-6233. doi: 10.1182/bloodadvances.2024014741.

32. Chemaly RF, El Haddad L, Winston DJ, et al. (2020) Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. Clin Infect Dis. 71 (9): 2365-2374. doi: 10.1093/cid/ciz1210.

33. Zamora D, Xie H, Wong E, Santiano C, Vivas-Jimenez A, Sadowska-Klasa A, Kampouri E, Stevens-Ayers T, Ueda Oshima M, Leisenring WM, Hill JA, Boeckh M. (2025) ELISPOT as a predictor of clinically significant cytomegalovirus infection after hematopoietic cell transplantation in letermovir recipients. Bone Marrow Transplant. 60 (8): 1137-1145. doi: 10.1038/s41409-025-02611-4.

**Table 1.**
Baseline characteristics

| Variables | Total (n=551) | PET (n=346) | LET (n=205) | *p*-value |
|---|---|---|---|---|
| | n (%) | n (%) | n (%) | |
| Age – Median (IQR) | 43 (31-55) | 41 (28-53) | 46 (33-60) | **<0.0001** |
| Male | 307 (55.7) | 188 (54.3) | 119 (58) | 0.397 |
| Underlying disease | | | | |
| Acute myeloid leukemia | 183 (33.2) | 114 (32.9) | 69 (33.7) | 0.864 |
| Acute lymphoblastic leukemia | 157 (28.5) | 106 (30.6) | 51 (24.9) | 0.147 |
| Myelodysplastic syndrome | 55 (10) | 31 (9) | 24 (11.7) | 0.298 |
| Non-Hodgkin lymphoma | 33 (6) | 22 (6.4) | 11 (5.4) | 0.635 |
| Hodgkin lymphoma | 31 (5.6) | 19 (5.5) | 12 (5.8) | 0.858 |
| Aplastic anemia | 31 (5.6) | 20 (5.8) | 11 (5.4) | 0.838 |
| Chronic myeloid leukemia | 27 (4.9) | 18 (5.2) | 9 (4.4) | 0.669 |
| Myelofibrosis | 20 (3.6) | 10 (2.9) | 10 (4.9) | 0.227 |
| Multiple myeloma | 4 (0.7) | 0 (0) | 4 (1.9) | 0.019 |
| Chronic lymphocytic leukemia | 1 (0.2) | 1 (0.3) | 0 (0) | 1 |
| Other | 9 (1.6) | 5 (1.4) | 4 (1.9) | 0.478 |
| Disease status | | | | |
| Complete remission | 370 (67.2) | 241 (69.7) | 129 (62.9) | 0.082 |
| Partial remission | 44 (8) | 26 (7.5) | 18 (8.8) | 0.596 |
| Recent diagnosis | 8 (1.5) | 6 (1.7) | 2 (1) | 0.716 |
| Refractory | 63 (11.4) | 32 (9.2) | 31 (15.1) | **0.036** |
| Relapsed | 27 (4.9) | 18 (5.2) | 9 (4.4) | 0.669 |
| Chronic phase | 39 (7.1) | 22 (6.4) | 17 (8.3) | 0.392 |
| Type of transplant | | | | |
| Match-related donor | 175 (31.8) | 149 (43.1) | 26 (12.7) | **<0.0001** |
| Mismatch-related donor | 10 (1.8) | 9 (2.6) | 1 (0.5) | 0.1 |
| Match-unrelated donor | 79 (14.3) | 42 (12.1) | 37 (18) | 0.055 |
| Mismatch-unrelated donor | 33 (6) | 13 (3.8) | 20 (9.8) | **0.004** |
| Haploidentical | 254 (46.1) | 133 (38.4) | 121 (59) | **<0.0001** |
| Alternative donor | 376 (68.2) | 197 (56.9) | 179 (87.3) | **<0.0001** |
| Source of stem cells | | | | |
| Peripheral blood | 532 (96.5) | 335 (96.8) | 197 (96.1) | 0.652 |
| Marrow | 17 (3.1) | 9 (2.6) | 8 (3.9) | 0.393 |
| Cord | 2 (0.4) | 2 (0.6) | 0 (0) | 0.531 |
| Type of conditioning | | | | |
| Myeloablative | 390 (70.8) | 252 (72.8) | 138 (67.3) | 0.168 |
| Non-myeloablative | 31 (5.6) | 16 (4.6) | 15 (7.3) | 0.184 |
| Reduced intensity | 130 (23.6) | 78 (22.5) | 52 (25.4) | 0.45 |
| T-cell depletion | 74 (13.4) | 42 (12.1) | 32 (15.6) | 0.248 |
| Anti-thymocyte globulin | 68 (12.3) | 40 (11.6) | 28 (13.7) | 0.469 |
| Alemtuzumab | 1 (0.2) | 0 (0) | 1 (0.5) | 0.372 |
| $CD34^{+}$-selection | 5 (0.9) | 2 (0.6) | 3 (1.5) | 0.366 |
| PTCy | 344 (62.4) | 179 (51.7) | 165 (80.5) | **<0.0001** |
| Prophylaxis for GvHD | | | | |
| Mycophenolate mofetil | 329 (59.7) | 174 (50.3) | 155 (75.6) | **<0.0001** |
| Cyclosporine | 121 (22) | 44 (12.7) | 77 (37.6) | **<0.0001** |
| Tacrolimus | 430 (78) | 301 (87) | 129 (62.9) | **<0.0001** |
| Methotrexate | 190 (34.5) | 158 (45.7) | 32 (15.6) | **<0.0001** |
| Primary engraftment failure | 20 (3.6) | 12 (3.5) | 8 (3.9) | 0.792 |
| Time to engraftment (days after HCT) – Median (IQR) | 16 (12-22) | 15 (11-20) | 18 (14-23) | **<0.0001** |

| | | | | |
|---|---|---|---|---|
| Lymphocyte count at 100 days after HCT (cell/mm$^3$) – Median (IQR) | 843 (502-1458) | 1085 (698-1651) | 605 (380-930) | **<0.0001** |
| CMV serostatus | | | | |
| R+/D+ | 445 (80.8) | 303 (87.6) | 142 (69.3) | **<0.0001** |
| R+/D- | 106 (19.2) | 43 (12.4) | 63 (30.7) | **<0.0001** |

Abbreviation: PET, pre-emptive therapy group; LET, Letermovir prophylaxis group; IQR, interquartile range; PTCy, post-transplant cyclophosphamide; HCT, hematopoietic cell transplant; R+/D-, recipient seropositive and donor seronegative; R+/D+, recipient and donor both seropositive. P-values were obtained using the chi-square or Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables. Bold: statistically significant.

**Table 2.**
Acute and Chronic Graft vs. Host Disease

| Variables | Total (n=551) | PET (n=346) | LET (n=205) | *p*-value |
|---|---|---|---|---|
| | n (%) | n (%) | n (%) | |
| **Acute GvHD** | 226 (41) | 136 (39.3) | 90 (43.9) | 0.289 |
| Time to onset (days after HCT) – Median (IQR) | 37 (26-54) | 38 (26-55) | 36 (25-51) | 0.447 |
| Severity: grade II-IV | 169 (30.7) | 112 (32.4) | 57 (27.8) | 0.261 |
| **Chronic GvHD** | 135 (24.5) | 115 (33.2) | 20 (9.8) | **<0.0001** |
| Time to onset (days after HCT) – Median (IQR) | 153 (110-222) | 154 (112-229) | 126 (108-195) | 0.179 |
| Severity: extensive | 93 (16.9) | 85 (24.6) | 8 (3.9) | **<0.0001** |

Abbreviation: PET, pre-emptive therapy group; LET, Letermovir prophylaxis group; IQR, interquartile range; HCT, hematopoietic cell transplant. P-values were obtained using the chi-square or Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables. Bold: statistically significant.

**Table 3.**
Risk factors for CMV infection and CMV disease

| Variables | Total (n=551) | PET (n=346) | LET (n=205) | *p*-value |
|---|---|---|---|---|
| | n (%) | n (%) | n (%) | |
| Age > 50 years | 200 (36.3) | 109 (31.5) | 91 (44.4) | **0.002** |
| CMV R+/D- | 106 (19.2) | 43 (12.4) | 63 (30.7) | **<0.0001** |
| Acute GvHD | 226 (41) | 136 (39.3) | 90 (43.9) | 0.289 |
| High dose corticosteroids use | 273 (49.5) | 185 (53.5) | 88 (42.9) | **0.016** |
| T-cell depletion | 74 (13.4) | 42 (12.1) | 32 (15.6) | 0.248 |
| Haploidentical transplant | 254 (46.1) | 133 (38.4) | 121 (59) | **<0.0001** |
| Mismatch-HLA donor | 43 (7.8) | 22 (6.4) | 21 (10.2) | 0.1 |
| Cord blood transplant | 2 (0.4) | 2 (0.6) | 0 (0) | 0.531 |
| Lymphopenia | 193 (35) | 94 (27.2) | 99 (48.3) | **<0.0001** |
| PTCy | 344 (62.4) | 179 (51.7) | 165 (80.5) | **<0.0001** |
| Number of risk factors – Median (IQR) | 3 (2-4) | 2 (2-4) | 4 (2-4) | **<0.0001** |
| High risk for CMV disease | 504 (91.5) | 305 (88.2) | 199 (97.1) | **0.0003** |

Abbreviation: PET, pre-emptive therapy group; LET, Letermovir prophylaxis group; CMV R+/D-, recipient seropositive and donor seronegative; GvHD, graft vs. host diseases; PTCy, post-transplant cyclophosphamide; IQR, interquartile range. P-values were obtained using the chi-square or Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables. Bold: statistically significant.

**Table 4.**
Primary outcomes

| Variables | Total (n=551) | PET (n=346) | LET (n=205) | *p*-value |
|---|---|---|---|---|
| | n (%) | n (%) | n (%) | |
| CS-CMVi | | | | |
| At day 100 after HCT | 203 (36.8) | 188 (54.3) | 15 (7.3) | **<0.0001** |
| At day 200 after HCT | 233 (42.3) | 192 (55.5) | 41 (20) | **<0.0001** |
| CMV disease | | | | |
| At day 100 after HCT | 26 (4.7) | 26 (7.5) | 0 (0) | **0.0001** |
| At day 200 after HCT | 34 (6.2) | 28 (8.2) | 6 (2.9) | **0.0164** |
| Peak viral load (IU/mL) Median (IQR) | 1079 (222-3851) | 1069 (211-3665) | 1120 (363-4300) | 0.94 |
| Peak viral load (copies/mL) Median (IQR) | 775 (215-2349) | 739 (222-2462) | 1016 (184-2278) | 0.14 |
| Admission for CS-CMVi | | | | |
| At day 100 after HCT | 152 (27.6) | 131 (37.9) | 21 (10.2) | **<0.0001** |
| At day 200 after HCT | 167 (30.3) | 137 (39.6) | 30 (14.6) | **<0.0001** |
| >1 episode of CS-CMVi | 56 (10.2) | 48 (13.9) | 8 (3.9) | **0.0002** |
| 200-day overall mortality | 108 (19.6) | 75 (21.7) | 33 (16.1) | 0.11 |
| CMV-related mortality | 5 (0.91) | 5 (1.45) | 0 (0) | 0.163 |

Abbreviation: PET, pre-emptive therapy group; LET, Letermovir prophylaxis group; CS-CMVi, clinically significant CMV infection; HCT, hematopoietic cell transplant. P-values were obtained using the chi-square or Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables. Bold: statistically significant.

**Table 5.**
Risk factors for 200-day overall mortality after HCT: univariate analysis

| Variables | Alive (n=443) | Dead (n=108) | HR (95% CI) | *p*-value |
|---|---|---|---|---|
| | n (%) | n (%) | | |
| Age > 50 years | 155 (35) | 45 (41.7) | 1.32 (0.86-2.03) | 0.196 |
| Acute myeloid leukemia | 144 (32.5) | 39 (36.1) | 1.17 (0.75-1.82) | 0.476 |
| Refractory disease | 49 (11.1) | 14 (13) | 1.19 (0.63-2.26) | 0.578 |
| Primary graft failure | 4 (0.9) | 16 (14.8) | 19.08 (5.93-79.63) | **<0.0001** |
| Haploidentical transplant | 198 (44.7) | 56 (51.9) | 1.33 (0.87-2.03) | 0.182 |
| Alternative donor | 298 (67.3) | 78 (72.2) | 1.26 (0.79-2.01) | 0.322 |
| Myeloablative conditioning | 313 (70.7) | 77 (71.3) | 1.03 (0.64-1.64) | 0.895 |
| Anti-thymocyte globulin | 54 (12.2) | 14 (13) | 1.07 (0.57-2.01) | 0.826 |
| PTCy | 274 (61.9) | 70 (64.8) | 1.13 (0.73-1.76) | 0.568 |
| aGvHD | 175 (39.5) | 51 (47.2) | 1.37 (0.89-2.09) | 0.143 |
| HD corticosteroids use for aGvHD | 136 (30.7) | 48 (44.4) | 1.81 (1.15-2.83) | **0.007** |
| CMV R+/D- | 79 (17.8) | 27 (25) | 1.53 (0.93-2.52) | 0.092 |
| Lymphopenia | 140 (31.6) | 53 (49.1) | 2.09 (1.33-3.27) | **0.001** |
| Letermovir primary prophylaxis | 172 (38.8) | 33 (30.6) | 0.69 (0.43-1.11) | 0.111 |
| >1 episode of CS-CMVi | 38 (8.8) | 17 (15.7) | 1.93 (1.04-3.57) | **0.032** |
| 100-day rehospitalization for CS-CMVi | 113 (25.5) | 39 (36.1) | 1.65 (1.02-2.63) | **0.027** |


Abbreviation: PTCy, post-transplant cyclophosphamide; aGvHD, acute graft vs. host diseases; HD, high dose; CMV R+/D-, recipient seropositive and donor seronegative; CS-CMVi, clinically significant CMV infection; HCT, hematopoietic cell transplant. P-values were obtained using the chi-square or Fisher's exact test for categorical variables. Bold: statistically significant.

**Table 6.**
Risk factors for 200-day overall mortality after HCT: multivariable Cox regression with propensity score adjustment

| Variables | Multivariable Cox regression | | Multivariable Cox regression adjusted for PS | |
|---|---|---|---|---|
| | HR (95% CI) | *p*-value | HR (95% CI) | *p*-value |
| Primary graft failure | 18.78 (5.98-59) | <0.0001 | 16.57 (5.23-52.52) | **<0.0001** |
| HD corticosteroids use for aGvHD | 1.9 (1.19-3.04) | 0.007 | 1.9 (1.19-3.04) | **0.007** |
| Lymphopenia | 1.87 (1.16-3.02) | 0.011 | 1.78 (1.10-2.89) | **0.019** |
| >1 episode of CS-CMVi | 1.39 (0.69-2.81) | 0.359 | 1.31 (0.64-2.67) | 0.454 |
| 100-day rehospitalization for CS-CMVi | 1.14 (0.66-1.95) | 0.641 | 1.18 (0.68-2.03) | 0.552 |
| Letermovir primary prophylaxis | 0.59 (0.35-1.01) | 0.055 | 0.51 (0.29-0.89) | **0.018** |


Abbreviation: HCT, hematopoietic cell transplant; PS, propensity score; HD, high dose; aGvHD, acute graft vs. host diseases; CS-CMVi, clinically significant CMV infection. Bold: statistically significant.

**Figure 1.** Selection of study population




Abbreviation: HCT, hematopoietic cell transplant; PET, pre-emptive therapy group; LET, Letermovir prophylaxis group.

**Figure 2.** Cumulative incidence curves of Clinically Significant CMV infection (CS-CMVi) and CMV disease




Abbreviation: PET, pre-emptive therapy group (blue line); LET, Letermovir prophylaxis group (green line); CS-CMVi, clinically significant CMV infection.